HK inno.N (195940) Stock Outlook 2026: A Homegrown P-CAB Blockbuster and Single-Product Risk
HK inno.N (KRX 195940) 2026 stock outlook. A qualitative deep dive into K-CAB (tegoprazan), Korea's homegrown P-CAB reflux drug and its competitive moat, the global licensing-out model, US clinical ambitions, the Condition hangover brand and IV-fluid base business, plus single-product dependence and drug-pricing risk for international investors.
HK inno.N 195940 K-CAB